CAPTRUST Financial Advisors’s Standard BioTools LAB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6K	Buy	28,742 +10,046	+54%	+$9.49K	﹤0.01%	3192
2026 Q1	$17.2K	Buy	18,696 +7,647	+69%	+$9.26K	﹤0.01%	2970
2025 Q4	$14.1K	Sell	11,049 -1,498	-12%	-$2.01K	﹤0.01%	2725
2025 Q3	$16.3K	Buy	12,547 +617	+5%	+$808	﹤0.01%	2611
2025 Q2	$14.3K	Buy	+11,930	New	+$13.2K	﹤0.01%	2484
2022 Q3	–	Sell	-1,030	Closed	-$2K	–	3138
2022 Q2	$2K	Hold	1,030	–	–	﹤0.01%	4480
2022 Q1	$4K	Hold	1,030	–	–	﹤0.01%	4253
2021 Q4	$4K	Sell	1,030 -41	-4%	-$192	﹤0.01%	4177
2021 Q3	$7K	Sell	1,071 -3,110	-74%	-$20.5K	﹤0.01%	3811
2021 Q2	$26K	Sell	4,181 -44	-1%	-$235	﹤0.01%	2938
2021 Q1	$19K	Buy	+4,225	New	+$23.2K	﹤0.01%	3033

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

CAPTRUST Financial Advisors's LAB Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Standard BioTools (LAB) stake by 54% in Q2 2026, buying an estimated $9.49K and bringing the position to 28,742 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

CAPTRUST Financial Advisors first reported a position in LAB in Q1 2021 and has held it in 11 quarters since. The position peaked at $26K in Q2 2021. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

CAPTRUST Financial Advisors held 28,742 shares of Standard BioTools worth $23.6K as of Q2 2026.
CAPTRUST Financial Advisors bought 10,046 Standard BioTools shares in Q2 2026, an estimated $9.49K.
Standard BioTools made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3192 holding.
CAPTRUST Financial Advisors first reported a position in Standard BioTools in Q1 2021 and has held it in 11 quarters since.
CAPTRUST Financial Advisors's Standard BioTools position peaked at $26K in Q2 2021.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.